



In mild to moderate AD Reach for EUCRISA for patients under your care



EUCRISA is the **first and only** topical PDE-4 inhibitor indicated for the topical treatment of mild to moderate AD in patients 2 years of age and older.^{1,2*}

AD=atopic dermatitis; PDE-4=phosphodiesterase-4.

* Comparative clinical significance unknown.

eucrisaTM
crisaborole ointment 2%

Photographs from the pivotal trials depicting success in ISGA at Day 29^{†,‡}



[†] Actual case. Individual results may vary. May not represent results for all patients. Adapted from Paller A, et al.

Significantly more patients achieved success in ISGA at Day 29 vs. vehicle (31.4% vs. 18%; $p \leq 0.001$)[†]

Success in ISGA:

defined as score of **CLEAR (0)** or **ALMOST CLEAR (1)** and ≥ 2 -grade improvement from baseline at Day 29

ISGA=Investigator's Static Global Assessment.

[‡] Results from the AD-302 study; a multicentre, double-blind, parallel-group, vehicle-controlled trial of patients aged 2–79 years (mean: 12.6 EUCRISA group; 11.8 vehicle group) with a 5–95% treatable body surface area (baseline mean: 17.9% EUCRISA group; 17.7% vehicle group). Patients were randomized 2:1 to receive EUCRISA (n=513) or vehicle (n=250) applied twice daily for 28 days.

Proven safety and tolerability profile¹

4-WEEK PIVOTAL TRIALS

Adverse reactions occurring in $\geq 1\%$ of patients in the 4-week pivotal trials

APPLICATION SITE PAIN[§]

4.45%

(n=45)

EUCRISA (N=1012)

1.20%

(n=6)

Proprietary vehicle ointment (N=499)

48-WEEK, OPEN-LABEL, SINGLE-ARM, LONG-TERM SAFETY STUDY[¶]

Most frequently reported adverse events in patients receiving EUCRISA intermittently (n=517) included:

- ✓ Atopic dermatitis
- ✓ Application site pain[§]
- ✓ Application site infection

Discontinuation rate due to adverse events was 2%.

[§] Application site pain refers to skin sensations such as burning or stinging.

[¶] 517 patients (including 454 patients aged 2–17 years) who completed the 28-day pivotal trials without safety issues that precluded further treatment were treated with EUCRISA intermittently for up to 48 weeks in 28-day on-treatment or off-treatment cycles.

OVER 600,000 PATIENTS TREATED
WITH EUCRISA WORLDWIDE¹

Consider EUCRISA as part of your treatment plan for patients with mild to moderate AD



Apply thin layer
topically twice daily



Ages 2 and up



Anywhere
on affected skin

Not for ophthalmic, oral,
or intravaginal use.

Relevant warnings and precautions

- Hypersensitivity reactions, including contact urticaria
- Use in pregnant and nursing women
- Use in geriatric patients

For more information

Consult the Product Monograph at <http://pfizer.ca/pm/en/Eucrisa.pdf> for information regarding adverse reactions, drug interactions, and dosing. The Product Monograph is also available by calling 1-800-463-6001.

References: 1. Data on file. Pfizer Canada ULC. 2. EUCRISA Product Monograph, Pfizer Canada ULC, June 11, 2018. 3. Paller A, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol* 2016;75(3):494–503.

|| Clinical significance unknown.

eucrisa™
crisaborole ointment 2%

© 2020 Pfizer Canada ULC
Kirkland, Quebec H9J 2M5
PP-CRI-CAN-0202-EN

™Anacor Pharmaceuticals, owner /
Pfizer Canada ULC, licensee



YOUR PARTNER
IN DERMATOLOGY